Related-Party Transactions |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Related Party Transactions [Abstract] | |
| RELATED-PARTY TRANSACTIONS | (10) RELATED-PARTY TRANSACTIONS The Company had several related-party agreements with Tallac Therapeutics, Inc., or Tallac. The details of these agreements are described in our notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 9, 2026. During the three months ended March 31, 2026, there were no material changes to these agreements. Tallac Collaboration Agreement During the three months ended March 31, 2026 and 2025, the Company recorded zero and $48 thousand, respectively, as R&D costs in relation to the collaboration agreement with Tallac, or the Tallac Collaboration Agreement. As of March 31, 2026 and December 31, 2025, the Company had no related to the Tallac Collaboration Agreement. |